본문 바로가기

Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q4Scopus Q2
저널
GUT AND LIVER7(4) · pp.406 · 2013
피인용
Web of Science 17KCI 7
JCR IF
JCR 2012 1.314
ISSN
1976-2283

저자

  1. 문지윤제1저자부산대학교, 부산대학교병원, 대학병원, KO
  2. 김광하교신저자부산대학교, 의과대학, 의과학과, KO
  3. You, Hyun Seok부산광역시의료원, Dept Internal Med, KO
  4. 이봉은부산대학교, 의과대학, 의학과, KO
  5. 류동엽부산대학교, 부산대학교병원, 대학병원, Dept Internal Med, KO
  6. 정재훈부산대학교, 부산대학교병원, 대학병원, KO
  7. 정정임부산대학교, 부산대학교병원, 대학병원, KO
  8. Jeong, Jae Hoon좋은삼선병원, Dept Internal Med, KO
  9. Song, Chul Soo좋은삼선병원, Dept Internal Med, KO
  10. 송근암부산대학교, 의과대학, 의학과, KO

초록

Background/Aims: Several rescue therapies have been recommended to eradicate Helicobacter pylori infection in patients with a failure of first-line eradication therapy, but they still fail in more than 20% of cases. The aim of this study was to evaluate the efficacy and safety of levofloxacin, metronidazole, and lansoprazole (LML) triple therapy relative to quadruple therapy as a second-line treatment. Methods: In total, 113 patients who failed first-line triple therapy for H. pylori infection were randomly assigned to two groups: LML for 7 days and tetracycline, bismuth subcitrate, metronidazole and lansoprazole (quadruple) for 7 days. Results: According to intention-to-treat analysis, the infection was eradicated in 38 of 56 patients (67.9%) in the LML group and 48 of 57(84.2%) in the quadruple group (p=0.042). Per-protocol analysis showed successful eradication in 38 of 52 patients (73.1%) from the LML group and 48 of 52 (92.3%) from the quadruple group (p=0.010). There were no significant differences in the adverse effects in either treatment group. Conclusions: LML therapy is less effective than quadruple therapy as a second-line treatment for H. pylori infection. Therefore, quadruple therapy should be considered as the primary second-line strategy for patients experiencing a failure of first-line H. pylori therapy in Korea.

키워드

Helicobacter pyloriTherapeuticsFailureLevofloxacinMetronidazolePROTON-PUMP INHIBITORRESCUE THERAPYTREATMENT FAILURECONTROLLED-TRIALERADICATIONMETAANALYSISCLARITHROMYCINAMOXICILLINMANAGEMENTRESISTANCE

식별자

WoS UID
000322057500004
KCI
ART001789282